Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
Melaiu O, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, Grząśko N, Moreno V, Jurczyszyn A, Jerez A, Watek M, Varkonyi J, Garcia-Sanz R, Kruszewski M, Dudziński M, Kadar K, Jacobsen SEH, Mazur G, Andersen V, Rybicka M, Zawirska D, Raźny M, Zaucha JM, Ostrovsky O, Iskierka-Jazdzewska E, Reis RM, Stępień A, Beider K, Nagler A, Druzd-Sitek A, Marques H, Martìnez-Lopez J, Lesueur F, Avet-Loiseau H, Vangsted AJ, Krawczyk-Kulis M, Butrym A, Jamroziak K, Dumontet C, Vogel U, Rymko M, Pelosini M, Subocz E, Szombath G, Sarasquete ME, Silvestri R, Morani F, Landi S, Campa D, Canzian F, Gemignani F. Melaiu O, et al. Among authors: subocz e. Int J Cancer. 2021 Apr 15;148(8):1887-1894. doi: 10.1002/ijc.33377. Epub 2020 Nov 20. Int J Cancer. 2021. PMID: 33152124 Free article.
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Walter-Croneck A, Grzasko N, Soroka-Wojtaszko M, Jurczyszyn A, Torosian T, Rymko M, Nowicki A, Druzd-Sitek A, Lech-Maranda E, Madro E, Zielinska P, Grygoruk-Wisniowska I, Blonska D, Usnarska-Zubkiewicz L, Potoczek S, Iskierka E, Masternak A, Holojda J, Dawidowska D, Gawron L, Barchnicka A, Olszewska-Szopa M, Rybicka M, Gontarska A, Jachalska A, Rzepecki P, Subocz E, Boguradzki P, Charlinski G, Dzierzak-Mietla M, Wisniewska-Piaty K, Swistek W, Kopacz A, Blajer-Olszewska B, Swiderska A, Dmoszynska A. Walter-Croneck A, et al. Among authors: subocz e. Leuk Res. 2014 Jul;38(7):788-94. doi: 10.1016/j.leukres.2014.04.011. Epub 2014 May 4. Leuk Res. 2014. PMID: 24862794
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L, Dębski J, Butrym A, Legieć W, Hus M, Dmoszyńska A, Stella-Hołowiecka B, Zaucha JM, Januszczyk J, Rymko M, Torosian T, Charliński G, Lech-Marańda E, Malenda A, Jurczyszyn A, Urbańska-Ryś H, Druzd-Sitek A, Błońska D, Urbanowicz A, Hołojda J, Pogrzeba J, Rzepecki P, Hałka J, Subocz E, Becht R, Zdziarska B, Dytfeld D, Nowicki A, Bołkun Ł, Kłoczko J, Knopińska-Posłuszny W, Zubkiewicz-Kucharska A, Kuliczkowski K. Usnarska-Zubkiewicz L, et al. Among authors: subocz e. Leuk Res. 2016 Jan;40:90-9. doi: 10.1016/j.leukres.2015.11.005. Epub 2015 Nov 15. Leuk Res. 2016. PMID: 26626207
Identification of miRSNPs associated with the risk of multiple myeloma.
Macauda A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A, Martinez Lopez J, Watek M, Butrym A, Sarasquete ME, Dudziński M, Jurczyszyn A, Druzd-Sitek A, Kruszewski M, Subocz E, Petrini M, Iskierka-Jażdżewska E, Raźny M, Szombath G, Marques H, Zawirska D, Chraniuk D, Halka J, Hove Jacobsen SE, Mazur G, García Sanz R, Dumontet C, Moreno V, Stępień A, Beider K, Pelosini M, Manuel Reis R, Krawczyk-Kulis M, Rymko M, Avet-Loiseau H, Lesueur F, Grząśko N, Ostrovsky O, Jamroziak K, Vangsted AJ, Jerez A, Tomczak W, Zaucha JM, Kadar K, Sainz J, Nagler A, Landi S, Gemignani F, Canzian F. Macauda A, et al. Among authors: subocz e. Int J Cancer. 2017 Feb 1;140(3):526-534. doi: 10.1002/ijc.30465. Epub 2016 Nov 9. Int J Cancer. 2017. PMID: 27718532 Free article.
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B, Budziszewska BK, Rybka J, Gil L, Subocz E, Długosz-Danecka M, Zawirska D, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Kopacz A, Szymczyk A, Czyż J, Lech-Marańda E, Warzocha K, Jamroziak K. Puła B, et al. Among authors: subocz e. Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557. Anticancer Res. 2018. PMID: 29715135
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.
Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F. Campa D, et al. Among authors: subocz e. Leuk Lymphoma. 2019 Jul;60(7):1803-1811. doi: 10.1080/10428194.2018.1551536. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30633655
Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
Drozd-Sokołowska J, Zaucha JM, Żółtak T, Jamroziak K, Grzybowska-Izydorczyk O, Witkowska M, Waszczuk-Gajda A, Kaźmierczak M, Szczepaniak A, Subocz E, Knopińska-Posłuszny W, Hołojda J, Kopińska A, Hus I, Rybka J, Wołowiec D, Kwiatkowski J, Hałaburda K, Smolewski P, Giebel S, Wiktor-Jędrzejczak W. Drozd-Sokołowska J, et al. Among authors: subocz e. Hematol Oncol. 2019 Oct;37(4):383-391. doi: 10.1002/hon.2624. Epub 2019 Jun 14. Hematol Oncol. 2019. PMID: 31026087
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.
Iskierka-Jażdżewska E, Canzian F, Stępień A, Martino A, Campa D, Stein A, Krawczyk-Kuliś M, Rybicka-Ramos M, Kyrcz-Krzemień S, Butrym A, Mazur G, Jurczyszyn A, Zawirska D, Grząśko N, Tomczak W, Subocz E, Wątek M, Pasiarski M, Rymko M, Całbecka M, Druzd-Sitek A, Walewski J, Kruszewski M, Raźny M, Zaucha JM, Dudziński M, Gaj P, Robak T, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Among authors: subocz e. Leuk Lymphoma. 2020 Mar;61(3):699-706. doi: 10.1080/10428194.2019.1689391. Epub 2019 Nov 20. Leuk Lymphoma. 2020. PMID: 31746254
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K. Pula B, et al. Among authors: subocz e. Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403. Anticancer Res. 2020. PMID: 32620653
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Puła B, Długosz-Danecka M, Salomon-Perzyński A, Szymczyk A, Subocz E, Budziszewska BK, Rybka J, Gil L, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Zaucha JM, Osowiecki M, Piszczek W, Steckiewicz P, Szukalski Ł, Hus M, Lech-Marańda E, Jurczak W, Jamroziak K. Puła B, et al. Among authors: subocz e. Adv Med Sci. 2020 Sep;65(2):371-377. doi: 10.1016/j.advms.2020.06.002. Epub 2020 Jul 10. Adv Med Sci. 2020. PMID: 32659728 Free article.
38 results